CXCR4 and CXCL12 (SDF-1) in prostate cancer: Inhibitory effects of human single chain Fv antibodies

Clinical Cancer Research

Volumn 10, Issue 16, 2004, Pages 5630-5639

  Vaday, Gayle G ^a,b   Hua, Shao Bing ^d   Peehl, Donna M ^c   Pauling, Michelle H ^d   Lin, Yu Huei ^d   Zhu, Li ^d   Lawrence, Diana M ^a   Foda, Hussein D ^a,b   Zucker, Stanley ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Genetastix Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AB124 ANTIBODY; AB125 ANTIBODY; CALCIUM; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM MOBILIZATION; CANCER CELL; CANCER CELL CULTURE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; METASTASIS; MORBIDITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TWO HYBRID SYSTEM;

BREAST NEOPLASMS; CALCIUM; CELL LINE, TUMOR; CHEMOKINES, CXC; CLONING, MOLECULAR; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MALE; PROSTATIC NEOPLASMS; RECEPTORS, CXCR4;

EID: 4143072487     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0633     Document Type: Article

References (49)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA - Cancer J Clin 2000;50:7-33.
2. Bubendorf L, Schopfer A, Wagner Uet al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31:578-83.
3. Cooper CR, Chay. CH, Gendernalik JD, et al. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer (Phila.) 2003; 97:739-47.
4. Adams GP, Schier R. Generating improved single-chain Fv molecules for tumor targeting. J Immunol Methods 1999;231:249-60.
5. Kortt AA, Dolezal O, Power BE, Hudson PJ. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng 2001; 18:95-108.
6. Vitaliti A, Wittmer M, Steiner R, Wyder L, Neri D, Klemenz R. Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. Cancer Res 2000;60:4311-4.
7. Schmidt M, Maurer-Gebhard M, Groner B, Kohler G, Brochmann-Santos G, Wels W. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic EGF receptors. Oncogene 1999;18:1711-21.
8. Cochet O, Gruel N, Fridman WH, Teillaud JL. Ras and p53 intracellular targeting with recombinant single-chain Fv (scFv) fragments: a novel approach for cancer therapy? Cancer Detect Prev 1999;23:506-10.
9. Wang L, Liu B, Schmidt M, Lu Y, Wels W, Fan Z. Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. Prostate 2001;47:21-8.
10. Jean D, Tellez C, Huang S, et al. Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene 2000;19:2721-30.
11. Adams GP, Shaller CC, Chappell LL, et al. Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol 2000;27:339-46.
12. Wang JM, Deng X, Gong W, Su S. Chemokines and their role in tumor growth and metastasis. J Immunol Methods 1998;200:1-17.
13. Bradstock KF, Makrynikola V, Bianchi A, Shen W, Hewson J, Gottlieb DJ. Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia (Baltimore) 2000;14:882-8.
14. Arai J, Yasukawa M, Yakushijin Y, Miyazaki T, Fujita S. Stromal cells in lymph node attract B-lymphoma cells via production of stromal cell-derived factor-1. Eur J Haematol 2000;64:323-32.
15. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science (Wash. DC) 1999;283:845-8.
16. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature (Lond.) 2001;410:50-6.
17. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-7.
18. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Streiter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003;167:1676-86.
19. Geminder H, Sagi-Assif O, Goldberg L, et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001;167:4747-57.
20. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003;89:462-73.
21. Sblattero D, Bradbury A. A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology 1998;3:271-8.
22. Nicholls PJ, Johnson VG, Blanford MD, Andrew SM. An improved method for generating single-chain antibodies from hybridomas. J Immunol Methods 1993;165:81-91.
23. Hua SB, Luo Y, Qiu M, Chan E, Zhou H, Zhu L. Construction of a modular yeast two-hybrid cDNA library from human EST clones for the human genome protein linkage map. Gene (Amst.) 1998;215:143-52.
24. Hua SB, Qiu M, Chan E, Zhu L, Luo Y. Minimum length of sequence homology required for in vivo cloning by homologous recombination in yeast. Plasmid 1997;38:91-6.
25. Peehl DM. Human prostatic epithelial cells. In: Freshney RI, Freshney MG, editors. Culture of epithelial cells, 2nd ed. New York: Wiley-Liss; 2002. p. 171-94.
26. Baribaud F, Edwards TG, Sharron M, et al. Antigenically distinct conformations of CXCR4. J Virol 2001;75:8957-67.
27. Barbero S, Bonavia R, Bajetto A, et al. Stromal cell-derived factor lalpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 2003;63:1969-74.
28. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill F. Epithelial cancer cell migration: a role for chemokine receptors. Cancer Res 2001;61:4961-5.
29. Koshiba T, Hosotani R, Miyamoto Y, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 2000;6: 3530-5.
30. Robledo MM, Barolome RA, Longo N, et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001;276:45098-105.
31. Kijima T, Maulik G, Ma PC, et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-kit in small cell lung cancer cells. Cancer Res 2002;62:6304-11.
32. Hwang JH, Hwang JH, Chung HK, et al. CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003;88:408-16.
33. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003;63:3833-9.
34. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature (Lond.) 2001;411:375-9.
35. Yeatman TJ, Nicholson GL. Molecular basis of tumor progression: mechanisms of organ-specific tumor metastasis. Semin Surg Oncol 1993;9:256-63.
36. Bruhl H, Cohen CD, Linder S, Kretzler M, Schlondorff D, Mack M. Post-translational and cell type-specific regulation of CXCR4 expression by cytokines. Eur J Immunol 2003;33:3028-37.
37. Bohm SK, Grady EF, Bunnett NW. Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochem J 1997; 322:1-18.
38. Moore BB, Arenberg DA, Stoy K, et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 1999; 154: 1503-12.
39. Giri D, Ittmann M. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 2001;159:139-47.
40. De Clercq E, Schols D. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists. Antivir Chem Chemother 2001;12 (Suppl 1):19-31.
41. Matthys P, Hatse S, Vermeire K, et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 2001;167:4686-92.
42. Juarez J, Bradstock KF, Gottlieb DJ, Bendall L. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia (Baltimore) 2003;17:1294-300.
43. Scotton CJ, Wilson JL, Scott KA, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002;62:5930-8.
44. Murakami T, Nakajima T, Koyanagi Y, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997;186:1389-93.
45. Tamamura H, Xu Y, Hattori T, et al. A low-molecular weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 1998;253:877-82.
46. Murakami T, Maki W, Cardones AR, et al. Expression of CXC Chemokine Receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002;62:7328-34.
47. Tamamura H, Hori A, Kanzaki N, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 2003;550:79-83.
48. Chen Y, Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res 2003;63:4801-4.
49. Maurer-Gebhard M, Schmidt M, Azemar M, et al. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res 1998;58:2661-6.